    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                       	     <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'GJDPMJAIEGHOIFAANOCCCIHOGNKIOADMHFOJFJAEEKCBDOLCEGABHPKEJNOAMCBAGOAEBFCPHGJNDBMDACDEEHPMPLJFJKMOEAAKPPEFMLBGGAGMDNEIIAEIGOJGECHO',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AESOMEPRAZOLE%20SODIUM%20%2D%20Esomeprazole%20Sodium%20Injection%2C%20Powder%2C%20Lyophilized%2C%20For%20So%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D069d7015%2Da2e4%2D4dbb%2D8255%2D2172e22a6300%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=20mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=20mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" src="image.cfm?type=img&name=20mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=40mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=40mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" src="image.cfm?type=img&name=40mgcarton.jpg&setid=069d7015-a2e4-4dbb-8255-2172e22a6300" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ESOMEPRAZOLE%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=ESOMEPRAZOLE" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=ESOMEPRAZOLE" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESOMEPRAZOLE[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESOMEPRAZOLE/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESOMEPRAZOLE/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESOMEPRAZOLE/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ESOMEPRAZOLE[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00363&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    47335-508-40,                                                                                                                                        	                                    47335-508-44,                                                                                                                                        	                                    47335-509-40,                                                                                                                                        	                                    47335-509-44                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Sun Pharma Global FZE</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">Abbreviated New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	01/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&amp;type=pdf&amp;name=069d7015-a2e4-4dbb-8255-2172e22a6300" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&amp;type=zip&amp;name=ESOMEPRAZOLE SODIUM">XML</a>                                                    </li>                                                                                                                                                            <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use ESOMEPRAZOLE SODIUM for injection safely and effectively. See full prescribing information for ESOMEPRAZOLE SODIUM for injection.   <br />ESOMEPRAZOLE SODIUM for Injection, for intravenous use    <br />Initial U.S. Approval: 2005  </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <p class="Highlighta">Warnings and Precautions, Interactions with Clopidogrel&nbsp;&nbsp; (<a href="#Section_5.9">5.4</a>)&nbsp;&nbsp; 10/2012 <br />Warnings and Precautions, <span class="Italics">Clostridium difficile </span>associated diarrhea (<a href="#Section_5.8">5.3</a>)&nbsp;&nbsp; 09/2012<br />Warnings and Precautions, Concomitant use of esomeprazole sodium with Methotrexate (<a href="#Section_5.7">5.9</a>)&nbsp;&nbsp;&nbsp;01/2012 </p>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">Esomeprazole sodium for injection&nbsp;is a proton pump inhibitor indicated for the treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients greater than one month of age, when oral therapy is not possible or appropriate.&nbsp; (<a href="#Section_1.1">1.1</a>) </p>    </div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <p class="Highlighta">GERD – with Erosive Esophagitis </p>     <ul class="Disc">      <li>Adults: Dose is either 20 mg or 40 mg esomeprazole given once daily by intravenous injection (no less than 3 minutes) or intravenous infusion (10 minutes to 30 minutes). (<a href="#Section_2.1">2.1</a>)</li>      <li>Pediatric: Give the following doses once daily as an intravenous infusion over 10 minutes to 30 minutes      <ul class="Disc">        <li>1 year to 17 years: (<a href="#Section_2.1">2.1</a>)        <ul class="Disc">          <li>Body weight less than 55 kg: 10 mg</li>          <li>Body weight 55 kg or greater: 20 mg</li>         </ul> </li>        <li>1 month to less than 1 year of age: 0.5 mg/kg (<a href="#Section_2.1">2.1</a>)</li>       </ul> </li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Esomeprazole sodium for injection is supplied as a freeze-dried cake containing 20 mg or 40 mg of esomeprazole per single-use vial. (<a href="#Section_3">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <p class="Highlighta">Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (angioedema and anaphylaxis have occurred). (<a href="#Section_4">4</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li>Symptomatic response to therapy with esomeprazole sodium does not preclude the presence of gastric malignancy. (<a href="#Section_5.1">5.1</a>)</li>      <li>Atrophic gastritis has been noted with long-term omeprazole therapy. (<a href="#Section_5.2">5.2</a>)</li>      <li>PPI therapy may be associated with increased risk of <span class="Italics">Clostridium difficile </span>associated diarrhea. (<a href="#Section_5.8">5.3</a>)</li>      <li>Avoid concomitant use of esomeprazole with clopidogrel. (<a href="#Section_5.9">5.4</a>)</li>      <li>Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (<a href="#Section_5.3">5.5</a>)</li>      <li>Hypomagnesemia has been reported rarely with prolonged treatment with PPIs (<a href="#Section_5.4">5.6</a>)</li>      <li>Avoid concomitant use of esomeprazole sodium with St John’s Wort or rifampin due to the potential reduction in esomeprazole levels (<a href="#Section_5.5">5.7</a>, <a href="#Section_7.2">7.2</a>)</li>      <li>Interactions with diagnostic investigations for Neuroendocrine Tumors: Increases in intragastric pH may result in hypergastrinemia and enterochromaffin-like cell hyperplasia and increased chromogranin A levels which may interfere with diagnostic investigations for neuroendocrine tumors. (<a href="#Section_5.6">5.8</a>, <a href="#Section_12.2">12.2</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most common adverse reactions (≥1%): </p>     <ul class="Disc">      <li>Headache, flatulence, nausea, abdominal pain, injection site reaction, diarrhea, dry mouth, dizziness/vertigo, constipation and pruritus (<a href="#Section_6.1">6.1</a>)</li>     </ul>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS,&nbsp;contact CARACO Pharmaceutical Laboratories Ltd. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li>Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, iron salts, erlotinib,&nbsp;and digoxin). Patients treated with esomeprazole and digoxin may need to be monitored for digoxin toxicity. (<a href="#Section_7">7</a>)</li>      <li>Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. (<a href="#Section_7">7</a>)</li>      <li>Esomeprazole may reduce the plasma levels of atazanavir, nelfinavir, and saquinavir. (<a href="#Section_7">7</a>)</li>      <li>Concomitant treatment with a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. (<a href="#Section_7">7</a>)</li>      <li>May increase systemic exposure of cilostazol and an active metabolite. Consider dose reduction (<a href="#Section_7">7</a>)</li>      <li>Clopidogrel: Esomeprazole decreases exposure to the active metabolite of clopidogrel. (<a href="#Section_7">7</a>)</li>      <li>Tacrolimus: Esomeprazole may increase serum levels of tacrolimus (<a href="#Section_7.2">7.2</a>)</li>      <li>Methotrexate: Esomeprazole may increase serum levels of methotrexate&nbsp; (<a href="#Section_7.3">7.3</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul class="Disc">      <li>Pregnancy: Based on animal data, may cause fetal harm. Limited human data. (<a href="#Section_8.1">8.1</a>)</li>      <li>Nursing Mothers: Caution should be exercised when administered to a nursing woman. (<a href="#Section_8.3">8.3</a>)</li>      <li>Hepatic Insufficiency<span class="Italics">:</span> For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of esomeprazole should not be exceeded. (<a href="#Section_2">2</a>, <a href="#Section_8.6">8.6</a>, <a href="#Section_12.3">12.3</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>   <p class="HighlightsRevision">Revised: 1/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Treatment of Gastroesophageal Reflux Disease (GERD) with Erosive Esophagitis </a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 GERD with Erosive Esophagitis</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Preparations for Use and Administration </a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Risk of Concomitant Gastric Malignancy </a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Atrophic Gastritis </a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Clostridium difficile associated diarrhea</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Interactions with Clopidogrel</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Bone Fracture </a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Hypomagnesemia </a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Concomitant use of Esomeprazole Sodium with St John’s Wort or Rifampin </a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Interactions with Investigations for Neuroendocrine Tumors </a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Concomitant use of Esomeprazole Sodium with Methotrexate</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience with Intravenous Esomeprazole Sodium </a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Clinical Trials Experience with Oral Esomeprazole Magnesium </a> </h2>   <h2> <a href="#section-6.3" class="toc">6.3 Postmarketing Experience </a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Interactions With Investigations of Neuroendocrine Tumors </a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Tacrolimus </a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Methotrexate</a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Hepatic Impairment </a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h2> <a href="#section-11.4" class="toc">12.4 Microbiology </a> </h2>   <h1> <a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-13" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Acid Suppression in Gastroesophageal Reflux Disease (GERD) </a> </h2>   <h1> <a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="Section_1"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_1.1"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Treatment of Gastroesophageal Reflux Disease (GERD) with Erosive Esophagitis </h2>    <p class="First">Esomeprazole sodium for injection is indicated for the short-term treatment of GERD with erosive esophagitis in adults and pediatric patients 1 month to 17 years, inclusively as an alternative to oral therapy when oral esomeprazole is not possible or appropriate.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="Section_2"></a>  <a name="section-2"></a>   <p></p>    <br />   <p class="First">Esomeprazole sodium for injection should not be administered concomitantly with any other medications through the same intravenous site and or tubing. The intravenous line should always be flushed with either 0.9% Sodium Chloride Injection, USP, Lactated Ringer’s Injection, USP or 5% Dextrose Injection, USP both prior to and after administration of esomeprazole sodium for injection.<br /> <br />The admixture should be stored at room temperature up to 30&deg;C (86&deg;F) and should be administered within the designated time period as listed in the Table 1 below. No refrigeration is required.</p>   <br />   <div class="scrollingtable">   <table border="0" cellpadding="0" cellspacing="0" width="410">     <caption>      <span>Table 1: </span>     </caption>     <tbody class="Headless">      <tr class="Botrule First">       <td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Diluent</span> <br /> </td>      <td class="Rrule" align="center" valign="top"><span class="Bold">Administer within:</span> <br /> </td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" valign="top">0.9% Sodium Chloride Injection, USP <br /> </td>      <td class="Rrule" align="center" valign="top">12 hours<br /> </td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" valign="top">Lactated Ringer’s Injection, USP <br /> </td>      <td class="Rrule" align="center" valign="top">12 hours<br /> </td>      </tr>      <tr class="Last">       <td class="Lrule Rrule" valign="top">5% Dextrose Injection, USP <br /> </td>      <td class="Rrule" align="center" valign="top">6 hours<br /> </td>      </tr>     </tbody>    </table>  </div>   <br />   <p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.<br /> <br />As soon as oral therapy is possible or appropriate, intravenous therapy with esomeprazole sodium for injection should be discontinued and the therapy should be continued orally.<br /> <br /> <span class="Bold">Special Populations</span> <br /> <span class="Italics">Hepatic Insufficiency: </span>No dosage adjustment is necessary in patients with mild to moderate liver impairment (Child Pugh Classes A and B). For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of esomeprazole should not be exceeded [<span class="Italics">see <a href="#Section_8.6">Use in Specific Populations (8.6)</a> and <a href="#Section_12.3">Clinical Pharmacology, Pharmacokinetics (12.3)</a></span>].</p>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 GERD with Erosive Esophagitis</h2>    <p class="First"> <span class="Bold">Adults</span> <br />The recommended adult dose is either 20 mg or 40 mg esomeprazole given once daily by intravenous injection (no less than 3 minutes) or intravenous infusion (10 minutes to 30 minutes).<br /> <br />Safety and efficacy of esomeprazole sodium for injection as a treatment of GERD patients with erosive esophagitis for more than 10 days have not been demonstrated.<br /> <br /> <span class="Bold">Pediatric</span> <br />The recommended doses for children ages 1 month to 17 years, inclusive, are provided below. Dose should be infused over 10 minutes to 30 minutes.<br /> <br />1 year to 17 years:<br />Body weight less than 55 kg: 10 mg<br />Body weight 55 kg or greater: 20 mg<br /> <br />1 month to less than 1 year of age: 0.5 mg/kg</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Preparations for Use and Administration </h2>    <p class="First"> <span class="Underline"><span class="Italics">Adults</span></span> <br /> <span class="Italics">Intravenous Injection (20 mg or 40 mg vial) over no less than 3 minutes</span> <br />The freeze-dried powder should be reconstituted with 5 mL of 0.9% Sodium Chloride Injection, USP. Withdraw 5 mL of the reconstituted solution and administer an intravenous injection over no less than 3 minutes.<br /> <br /> <span class="Italics">Intravenous Infusion (20 mg or 40 mg) over 10 minutes to 30 minutes</span> <br />A solution for intravenous infusion is prepared by first reconstituting the contents of one vial with 5 mL of 0.9% Sodium Chloride Injection, USP, Lactated Ringer’s Injection, USP or 5% Dextrose Injection, USP and further diluting the resulting solution to a final volume of 50 mL. The solution (admixture) should be administered as an intravenous infusion over a period of 10 minutes to 30 minutes.<br /> <br />The reconstituted solution should be stored at room temperature up to 30&deg;C (86&deg;F) and administered within 12 hours after reconstitution. No refrigeration is required.<br /> <br /> <span class="Underline"><span class="Italics">Pediatric Population</span></span> <br /> <span class="Italics">Intravenous Infusion over 10 minutes to 30 minutes (0.5 mg/kg) for patients ages 1 month to less than 1 year of age</span> <br />A solution for intravenous infusion is prepared by first reconstituting the contents of one vial with 5 mL of 0.9% Sodium Chloride Injection, USP and further diluting the resulting solution to a final volume of 50 mL. The resultant concentration after diluting to a final volume of 50 mL is as follows:<br /> <br />40 mg vial: 0.8 mg/mL<br />20 mg vial: 0.4 mg/mL<br /> <br />Withdraw appropriate amount of volume for desired dose (0.5 mg/kg) and administer as an intravenous infusion over 10 minutes to 30 minutes<br /> <br /> <span class="Italics">Intravenous Infusion (10 mg and 20 mg) over 10 minutes to 30 minutes for Pediatric Patients, ages 1 year to 17 years of age</span> <br /> <span class="Italics">40 mg vial</span> <br />A solution for intravenous infusion is prepared by first reconstituting the contents of one vial with 5 mL of 0.9% Sodium Chloride Injection, USP and further diluting the resulting solution to a final volume of 50 mL. The resultant concentration after diluting to a final volume of 50 mL is 0.8 mg/mL.<br /> <br />20 mg dose: Withdraw 25 mL of the final solution and administer as an intravenous infusion over 10 minutes to 30 minutes<br /> <br />10 mg dose: Withdraw 12.5 mL of the final solution and administer as an intravenous infusion over 10 minutes to 30 minutes<br /> <br /> <span class="Italics">20 mg vial</span> <br />A solution for intravenous infusion is prepared by first reconstituting the contents of one vial with 5 mL of 0.9% Sodium Chloride Injection, USP and further diluting the resulting solution to a final volume of 50 mL. The resultant concentration after diluting to a final volume of 50 mL is 0.4 mg/mL.<br /> <br />20 mg dose: Administer the final solution (50 mL) as an intravenous infusion over 10 minutes to 30 minutes<br /> <br />10 mg dose: Withdraw 25 mL of the final solution and administer as an intravenous infusion over 10 minutes to 30 minutes</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="Section_3"></a>  <a name="section-3"></a>   <p></p>    <br />   <p class="First">Esomeprazole sodium for injection is supplied as a white to off-white, freeze-dried cake containing 20 mg or 40&nbsp;mg of esomeprazole per single-use vial.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="Section_4"></a>  <a name="section-4"></a>   <p></p>    <br />   <p class="First">Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (angioedema and anaphylaxis have occurred).</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="Section_5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Risk of Concomitant Gastric Malignancy </h2>    <p class="First">Symptomatic response to therapy with esomeprazole sodium does not preclude the presence of gastric malignancy.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Atrophic Gastritis </h2>    <p class="First">Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which esomeprazole is an enantiomer.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.8"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Clostridium difficile associated diarrhea</h2>    <p class="First">Published observational studies suggest that PPI therapy like esomeprazole sodium may be associated with an increased risk of <span class="Italics">Clostridium difficile </span>associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [<span class="Italics">see <a href="#Section_6.2">Adverse Reactions (6.2)</a></span>].<br /> <br />Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.9"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Interactions with Clopidogrel</h2>    <p class="First">Avoid concomitant use of esomeprazole sodium with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as esomeprazole, that inhibit CYP2C19 activity. Concomitant use of clopidogrel with 40 mg esomeprazole reduces the pharmacological activity of clopidogrel. When using esomeprazole sodium consider alternative anti-platelet therapy. [<span class="Italics">see <a href="#Section_7">Drug Interactions (7)</a> and <a href="#Section_12.3">Pharmacokinetics (12.3)</a></span>]</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.3"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Bone Fracture </h2>    <p class="First">Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines. [<span class="Italics">see <a href="#Section_2">Dosage and Administration (2)</a> and <a href="#Section_6.3">Adverse Reactions (6.3)</a></span>]</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.4"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Hypomagnesemia </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Hypomagnesemia,</span> symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.<br /> <br /> <span class="XmChange">For patients</span> expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically. [<span class="Italics">See <a href="#Section_6.3">Adverse Reactions (6.3)</a></span>]</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.5"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Concomitant use of Esomeprazole Sodium with St John’s Wort or Rifampin </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Drugs</span> which induce CYP2C19 or CYP3A4 (such as St John’s Wort or rifampin) can substantially decrease esomeprazole concentrations [<span class="Italics">see <a href="#Section_7">Drug Interactions (7)</a></span>]. Avoid concomitant use of esomeprazole sodium with St John’s Wort or rifampin.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.6"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Interactions with Investigations for Neuroendocrine Tumors </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Serum </span>chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop esomeprazole treatment before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_5.7"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Concomitant use of Esomeprazole Sodium with Methotrexate</h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Literature</span> suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration a temporary withdrawal of the PPI may be considered in some patients. [<span class="Italics">see <a href="#Section_7.3">Drug Interactions (7.3)</a></span>]</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="Section_6"></a>  <a name="section-6"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience with Intravenous Esomeprazole Sodium </h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br /> <br />Adults<br />The safety of intravenous esomeprazole is based on results from clinical trials conducted in three different populations including patients having symptomatic GERD with or without a history of erosive esophagitis (n=199), patients with erosive esophagitis (n=160), and healthy subjects (n=204). Adverse experiences occurring in &gt;1% of patients treated with intravenous esomeprazole (n=359) in trials are listed below by body system:<br /> <br /> <span class="Bold">Symptomatic GERD and Erosive Esophagitis Trials</span> <br />The data described below reflect exposure to esomeprazole sodium for injection in 359 patients. Esomeprazole sodium for injection was studied only in actively-controlled trials. The population was 18 to 77 years of age; 45% Male, 52% Caucasian, 17% Black, 3% Asian, 28% Other, and had either erosive reflux esophagitis (44%) or GERD (56%). Most patients received doses of either 20 mg or 40 mg either as an infusion or an injection.</p>    <br />    <br />    <div class="scrollingtable">    <table border="0" cellpadding="0" cellspacing="0" width="423">      <caption>       <span>Table 2: Adverse reactions occurring at an incidence ≥ 1% in the esomeprazole sodium for injection group </span>      </caption>      <tbody class="Headless">       <tr class="Botrule First">        <td class="Lrule Rrule" valign="top"><span class="Bold">Adverse Reactions </span> <br /> </td>       <td class="Rrule" align="center" valign="top"><span class="Bold">% of patients </span> <br /> <span class="Bold">Esomeprazole Intravenous </span> <br /> <span class="Bold">(n=359)</span> <br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Headache <br /> </td>       <td class="Rrule" align="center" valign="top">10.9<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Flatulence <br /> </td>       <td class="Rrule" align="center" valign="top">10.3<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Nausea <br /> </td>       <td class="Rrule" align="center" valign="top">6.4<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Abdominal pain <br /> </td>       <td class="Rrule" align="center" valign="top">5.8<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Diarrhea <br /> </td>       <td class="Rrule" align="center" valign="top">3.9<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Mouth dry <br /> </td>       <td class="Rrule" align="center" valign="top">3.9<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Dizziness/vertigo <br /> </td>       <td class="Rrule" align="center" valign="top">2.8<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Constipation <br /> </td>       <td class="Rrule" align="center" valign="top">2.5<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">Injection site reaction <br /> </td>       <td class="Rrule" align="center" valign="top">1.7<br /> </td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" valign="top">Pruritus <br /> </td>       <td class="Rrule" align="center" valign="top">1.1<br /> </td>       </tr>      </tbody>     </table>   </div>    <p>Intravenous treatment with esomeprazole 20 mg and 40 mg administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of esomeprazole.<br /> <br /> <span class="Bold">Pediatric</span> <br />In a randomized, open-label, multi-national study to evaluate the pharmacokinetics of repeated intravenous doses of once daily esomeprazole, esomeprazole was well tolerated in pediatric patients 1 month to 17 years old, inclusive.&nbsp;The safety results are consistent with the known safety profile of esomeprazole and no unexpected safety signals were identified. [<span class="Italics">See <a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>]</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Clinical Trials Experience with Oral Esomeprazole Magnesium </h2>    <p class="First"> <span class="Italics">Adult</span> <br />The safety of oral esomeprazole magnesium </p>    <span class="Bold"></span>    <p>was evaluated in over 15,000 patients (aged 18 to 84 years) in clinical trials worldwide including over 8,500 patients in the United States and over 6,500 patients in Europe and Canada. Over 2,900 patients were treated in long-term studies for up to 6 to 12 months. In general, esomeprazole magnesium </p>    <span class="Bold"></span>    <p>was well tolerated in both short and long-term clinical trials.<br /> <br />The safety in the treatment of healing of erosive esophagitis was assessed in four randomized comparative clinical trials, which included 1,240 patients on esomeprazole magnesium </p>    <span class="Bold"></span>    <p>20 mg, 2,434 patients on esomeprazole magnesium </p>    <span class="Bold"></span>    <p>40 mg, and 3,008 patients on omeprazole 20 mg daily.&nbsp; The most frequently occurring adverse events (≥1%) in all three groups were headache (5.5, 5, and 3.8, respectively) and diarrhea (no difference among the three groups). Nausea, flatulence, abdominal pain, constipation, and dry mouth occurred at similar rates among patients taking esomeprazole magnesium </p>    <span class="Bold"></span>    <p>or omeprazole.<br /> <br />Additional adverse events that were reported as possibly or probably related to esomeprazole magnesium </p>    <span class="Bold"></span>    <p>with an incidence &lt;1% are listed below by body system:<br /> <br /> <span class="Bold"><span class="Italics">Body as a Whole</span>:</span> abdomen enlarged, allergic reaction, asthenia, back pain, chest pain, chest pain substernal, facial edema, peripheral edema, hot flushes, fatigue, fever, flu-like disorder, generalized edema, leg edema, malaise, pain, rigors; <span class="Bold"><span class="Italics">Cardiovascular</span>:</span> flushing, hypertension, tachycardia; <span class="Bold"><span class="Italics">Endocrine</span>:</span> goiter; <span class="Bold"><span class="Italics">Gastrointestinal</span>:</span> bowel irregularity, constipation aggravated, dyspepsia, dysphagia, dysplasia GI, epigastric pain, eructation, esophageal disorder, frequent stools, gastroenteritis, GI hemorrhage, GI symptoms not otherwise specified, hiccup, melena, mouth disorder, pharynx disorder, rectal disorder, serum gastrin increased, tongue disorder, tongue edema, ulcerative stomatitis, vomiting; <span class="Bold"><span class="Italics">Hearing: </span></span>earache, tinnitus; <span class="Bold"><span class="Italics">Hematologic</span>:</span> anemia, anemia hypochromic, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia; <span class="Bold"><span class="Italics">Hepatic</span>: </span>bilirubinemia, hepatic function abnormal, SGOT increased, SGPT increased; <span class="Bold"><span class="Italics">Infections and Infestations</span></span>: <span class="Italics">Clostridium difficile </span>associated diarrhea; <span class="Bold"><span class="Italics">Metabolic/Nutritional: </span></span>glycosuria, hyperuricemia, hyponatremia, increased alkaline phosphatase, thirst, vitamin B12 deficiency, weight increase, weight decrease; <span class="Bold"><span class="Italics">Musculoskeletal</span>:</span> arthralgia, arthritis aggravated, arthropathy, cramps, fibromyalgia syndrome, hernia, polymyalgia rheumatica; <span class="Bold"><span class="Italics">Nervous System/Psychiatric</span>: </span>anorexia, apathy, appetite increased, confusion, depression aggravated, dizziness, hypertonia, nervousness, hypoesthesia, impotence, insomnia, migraine, migraine aggravated, paresthesia, sleep disorder, somnolence, tremor, vertigo, visual field defect; <span class="Bold"><span class="Italics">Reproductive</span>:</span> dysmenorrhea, menstrual disorder, vaginitis; <span class="Bold"><span class="Italics">Respiratory</span>:</span> asthma aggravated, coughing, dyspnea, larynx edema,&nbsp;pharyngitis, rhinitis, sinusitis; <span class="Bold"><span class="Italics">Skin and Appendages</span>:</span> acne, angioedema, dermatitis, pruritus, pruritus ani, rash, rash erythematous, rash maculo-papular, skin inflammation, sweating increased, urticaria; <span class="Bold"><span class="Italics">Special Senses: </span></span>otitis media, parosmia, taste loss, taste perversion; <span class="Bold"><span class="Italics">Urogenital</span>:</span> abnormal urine, albuminuria, cystitis, dysuria, fungal infection, hematuria, micturition frequency, moniliasis, genital moniliasis, polyuria; <span class="Bold"><span class="Italics">Visual</span>:</span> conjunctivitis, vision abnormal.<br /> <br />Endoscopic findings that were reported as adverse events include: duodenitis, esophagitis, esophageal stricture, esophageal ulceration, esophageal varices, gastric ulcer, gastritis, hernia, benign polyps or nodules, Barrett’s esophagus, and mucosal discoloration.<br /> <br />The incidence of treatment-related adverse events during 6&shy;-month maintenance treatment was similar to placebo. There were no differences in types of related adverse events seen during maintenance treatment up to 12 months compared to short-term treatment.<br /> <br />Two placebo-controlled studies were conducted in 710 patients for the treatment of symptomatic gastroesophageal reflux disease. The most common adverse events that were reported as possibly or probably related to esomeprazole magnesium </p>    <span class="Bold"></span>    <p>were diarrhea (4.3%), headache (3.8%), and abdominal pain (3.8%).<br /> <br />The following potentially clinically significant laboratory changes in clinical trials, irrespective of relationship to esomeprazole magnesium, were reported in ≤ 1% of patients: increased creatinine, uric acid, total bilirubin, alkaline phosphatase, ALT, AST, hemoglobin, white blood cell count, platelets, serum gastrin, potassium, sodium, thyroxine and thyroid stimulating hormone [<span class="Italics">see <a href="#Section_12.2">Clinical Pharmacology, Endocrine Effects (12.2)</a></span> for further information on thyroid effects]. Decreases were seen in hemoglobin, white blood cell count,platelets, potassium, sodium, and thyroxine.<br /> <br /> <span class="Italics">Pediatric</span> <br />The safety of oral esomeprazole magnesium </p>    <span class="Bold"></span>    <p>was evaluated in 316 pediatric and adolescent patients aged 1 to 17 years in four clinical trials for the treatment of symptomatic GERD [<span class="Italics">see Clinical Studies (14.2)</span>]. In 109 pediatric patients aged 1 to 11 years, the most frequently reported (at least 1%) treatment-related adverse reactions in these patients were diarrhea (2.8%), headache (1.9%) and somnolence (1.9%).&nbsp; In 149 pediatric patients aged 12 to 17 years the most frequently reported (at least 2%) treatment-related adverse reactions in these patients were headache (8.1%), abdominal pain (2.7%), diarrhea (2%), and nausea (2%). No new safety concerns were identified in pediatric patients.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_6.3"></a>   <a name="section-6.3"></a>    <p></p>    <h2>6.3 Postmarketing Experience </h2>    <p class="First">The following adverse reactions have been identified during post-approval use of esomeprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br /> <br />Postmarketing Reports - There have been spontaneous reports of adverse events with postmarketing use of esomeprazole. These reports occurred rarely and are listed below by body system:<br /> <br /> <span class="Italics"><span class="Bold">Blood And Lymphatic System Disorders</span>:</span> agranulocytosis, pancytopenia; <span class="Bold"><span class="Italics">Eye Disorders: </span></span>blurred vision; <span class="Bold"><span class="Italics">Gastrointestinal Disorders:</span></span> pancreatitis; stomatitis; microscopic colitis; <span class="Bold"><span class="Italics">Hepatobiliary Disorders: </span></span>hepatic failure, hepatitis with or without jaundice; <span class="Bold"><span class="Italics">Immune System Disorders: </span></span>anaphylactic reaction/shock; <span class="Bold"><span class="Italics">Infections and Infestations: </span></span>GI candidiasis; <span class="Bold"><span class="Italics">Metabolism and nutritional disorders:</span></span> hypomagnesemia<span class="Bold"><span class="Italics">; Musculoskeletal And Connective Tissue Disorders: </span></span>muscular weakness, myalgia, bone fracture; <span class="Bold"><span class="Italics">Nervous System Disorders</span></span>: hepatic encephalopathy, taste disturbance; <span class="Bold"><span class="Italics">Psychiatric Disorders: </span></span>aggression, agitation, depression, hallucination; <span class="Bold"><span class="Italics">Renal and Urinary Disorders</span></span>: interstitial nephritis; <span class="Bold"><span class="Italics">Reproductive System and Breast Disorders:</span></span> gynecomastia; <span class="Bold"><span class="Italics">Respiratory, Thoracic and Mediastinal Disorders: </span></span>bronchospasm; <span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders: </span></span>alopecia, erythema multiforme, hyperhidrosis, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN, some fatal).<br /> <br />Other adverse events not observed with esomeprazole magnesium, but occurring with omeprazole can be found in the omeprazole package insert, <span class="Bold">ADVERSE REACTIONS</span> section.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="Section_7"></a>  <a name="section-7"></a>   <p></p>    <br />   <p class="First">Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.<br /> <br /> <span class="Italics">In vitro </span>and <span class="Italics">in vivo</span> studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected. Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin. Postmarketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.<br /> <br />Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme. Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam. Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.&nbsp;However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.<br /> <br /> <span class="Italics">Clopidogrel</span> <br />Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of esomeprazole sodium with clopidogrel. When using esomeprazole sodium, consider use of alternative anti-platelet [<span class="Italics">see <a href="#Section_12.3">Pharmacokinetics (12.3)</a></span>].<br /> <br />Omeprazole acts as an inhibitor of CYP2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased C<span class="Sub">max</span> and AUC of cilostazol by 18% and 26%, respectively. C<span class="Sub">max</span> and AUC of one of its active metabolites, 3,4-dihydro-cilostazol, which has 4 to 7 times the activity of cilostazol, were increased by 29% and 69%, respectively. Coadministration of cilostazol with esomeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite. Therefore, a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered.<br /> <br />Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. Dose adjustment of esomeprazole is not normally required for the recommended doses. However, in patients who may require higher doses, dose adjustment may be considered.<br /> <br />Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased esomeprazole serum levels. Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with St. John’s wort, an inducer of CYP3A4. In a cross-over study in 12 healthy male subjects, St John’s wort (300 mg three times daily for 14 days) significantly decreased the systemic exposure of omeprazole in CYP2C19 poor metabolizers (C<span class="Sub">max</span> and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolizers (C<span class="Sub">max</span> and AUC decreased by 49.6% and 43.9%, respectively). Avoid concomitant use of St. John’s Wort or rifampin with esomeprazole sodium. <br />&nbsp;Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.<br /> <br />Concomitant use of atazanavir and proton pump inhibitors is not recommended. Coadministration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.<br /> <br />Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, C<span class="Sub">max</span> by 37% and 89% and C<span class="Sub">min</span> by 39% and 75%, respectively, for nelfinavir and M8. Following multiple doses of atazanavir (400 mg daily) and omeprazole (40 mg daily, 2 hr before atazanavir), AUC was decreased by 94%, C<span class="Sub">max</span> by 96%, and C<span class="Sub">min</span> by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in C<span class="Sub">max</span> by 75% and in C<span class="Sub">min</span> by 106% following multiple dosing of saquinavir/ritonavir (1,000 mg/100 mg) twice daily for 15 days with omeprazole 40 mg daily coadministered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.<br /> <br />Studies evaluating concomitant administration of esomeprazole and either naproxen (non-selective NSAID) or rofecoxib (COX-2 selective NSAID) did not identify any clinically relevant changes in the pharmacokinetic profiles of esomeprazole or these NSAIDs.<br /> <br />Esomeprazole inhibits gastric acid secretion. Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects). Esomeprazole is an enantiomer of omeprazole. Coadministration of digoxin with esomeprazole is expected to increase the systemic exposure of digoxin. Therefore, patients may need to be monitored when digoxin is taken concomitantly with esomeprazole.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Interactions With Investigations of Neuroendocrine Tumors </h2>    <p class="First">Drug-induced decrease in gastric acidity results in enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors [<span class="Italics">see <a href="#Section_5.6">Warnings and Precautions (5.8)</a> and <a href="#Section_12.2">Clinical Pharmacology (12.2)</a></span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Tacrolimus </h2>    <p class="First">Concomitant administration of esomeprazole and tacrolimus may increase the serum levels of tacrolimus.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_7.3"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Methotrexate</h2>    <p class="First">Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted [<span class="Italics">see <a href="#Section_5.7">Warnings and Precautions (5.9)</a></span>].</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="Section_8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="Section_8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <p class="First"> <span class="Italics">Teratogenic Effects. Pregnancy Category B</span> <br />Teratology studies have been performed in rats at oral doses up to 280 mg/kg/day (about 57 times the human dose on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 35 times the human dose on a body surface area basis) and have revealed no evidence of impaired fertility or harm to the fetus due to esomeprazole.&nbsp;There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.<br /> <br />Teratology studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 56 times the human dose on a body surface area basis) and in rabbits at doses up to 69 mg/kg/day (about 56 times the human dose on a body surface area basis) did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 5.5 to 56 times the human dose on a body surface area basis) produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138 mg/kg/day (about 5.6 to 56 times the human doses on a body surface area basis). There are no adequate and well-controlled studies in pregnant women. Sporadic reports have been received of congenital abnormalities occurring in infants born to women who have received omeprazole during pregnancy.</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="Section_8.3"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">The excretion of esomeprazole in milk has not been studied. However, omeprazole concentrations have been measured in breast milk of a woman following oral administration of 20 mg. Because esomeprazole is likely to be excreted in human milk, because of the potential for serious adverse reactions in nursing infants from esomeprazole, and because of the potential for tumorigenicity shown for omeprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="Section_8.4"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">The safety and effectiveness of esomeprazole sodium </p>    <span class="Bold"></span>    <p>for injection have been established in pediatric patients 1 month to 17 years of age for short-term treatment of GERD with Erosive Esophagitis [<span class="Italics">see <a href="#Section_12.3">Clinical Pharmacology, Pharmacokinetics (12.3)</a></span>]. However, effectiveness has not been established in patients less than 1 month of age.<br /> <br /> <span class="Italics">1 month to 17 years of age</span> <br />Use of esomeprazole sodium for injection in pediatric patients 1 month to 17 years of age for short-term treatment of GERD with Erosive Esophagitis is supported by: a) results observed from a pharmacokinetic (PK) study on esomeprazole sodium for injection performed in pediatric patients, b) predictions from a population PK model comparing I.V. PK data between adult and pediatric patients, and c) relationship between exposure and pharmacodynamic results obtained from adult I.V. and pediatric oral data and d) PK results already included in the current approved labeling and from adequate and well-controlled studies that supported the approval of esomeprazole sodium for injection for adults.<br /> <br /> <span class="Italics">Neonates 0 to 1 month of age</span> <br />Following administration of esomeprazole sodium for injection in neonates the geometric mean (range) for CL was 0.17 L/h/kg (0.04 L/h/kg to 0.32 L/h/kg).</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="Section_8.5"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Of the total number of patients who received oral esomeprazole magnesium in clinical trials, 1,459 were 65 to 74 years of age and 354 patients were ≥ 75 years of age.<br /> <br />No overall differences in safety and efficacy were observed between the elderly and younger individuals, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_8.6"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Hepatic Impairment </h2>    <p class="First">No dosage adjustment is necessary in patients with mild to moderate hepatic insufficiency (Child Pugh Classes A and B). For patients with severe hepatic insufficiency (Child Pugh Class C) a dose of 20 mg once daily should not be exceeded [<span class="Italics">see <a href="#Section_2">Dosage and Administration (2)</a> and <a href="#Section_12.3">Clinical Pharmacology, Pharmacokinetics (12.3)</a></span>].</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="Section_10"></a>  <a name="section-9"></a>   <p></p>    <p class="First">The minimum lethal dose of esomeprazole sodium in rats after bolus administration was 310 mg/kg (about 62 times the human dose on a body surface area basis). The major signs of acute toxicity were reduced motor activity, changes in respiratory frequency, tremor, ataxia and intermittent clonic convulsions.<br /> <br />The symptoms described in connection with deliberate esomeprazole overdose (limited experience of doses in excess of 240 mg/day) are transient. Single doses of 80 mg of esomeprazole were uneventful. Reports of overdosage with omeprazole in humans may also be relevant. Doses ranged up to 2,400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience (see omeprazole package insert - <span class="Bold">ADVERSE REACTIONS</span>). No specific antidote for esomeprazole is known. Since esomeprazole is extensively protein bound, it is not expected to be removed by dialysis. In the event of overdosage, treatment should be symptomatic and supportive.<br /> <br />As with the management of any overdose, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug overdose, a certified Regional Poison Control Center should be contacted. Telephone numbers are listed in the Physicians’ Desk Reference (PDR) or local telephone book.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="Section_11"></a>  <a name="section-10"></a>   <p></p>    <p class="First">The active ingredient in esomeprazole sodium for injection is (<span class="Italics">S</span>)-5-methoxy-2[[(4-methoxy-3,5&shy;-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 <span class="Italics">H</span>-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">18</span>N<span class="Sub">3</span>O<span class="Sub">3</span>SNa with molecular weight of 367.4 g/mol (sodium salt) and 345.4 g/mol (parent compound). Esomeprazole sodium is freely soluble in water. The structural formula is:</p>   <br />   <div class="Figure">    <img src="image.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&name=chemical%2Dstructure%2Ejpg" alt="chemical-structure" />  </div>   <br />   <p>Esomeprazole sodium for injection is supplied as sterile, freeze-dried, white to off-white, porous cake or powder in a 5 mL vial, intended for intravenous administration after reconstitution with 0.9% Sodium Chloride Injection, USP; Lactated Ringer’s Injection, USP or 5% Dextrose Injection, USP. Esomeprazole sodium for injection contains esomeprazole sodium 21.3 mg or 42.5 mg equivalent to esomeprazole 20 mg or 40 mg, edetate disodium 1.5 mg and sodium hydroxide q.s. for pH adjustment. The pH of reconstituted solution of esomeprazole sodium for injection depends on the reconstitution volume and is in the pH range of 9 to 11. The stability of esomeprazole sodium in aqueous solution is strongly pH dependent. The rate of degradation increases with decreasing pH.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="Section_12"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="Section_12.1"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<span class="Sup">+</span>/K<span class="Sup">+</span>&shy;-ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 mg to 40 mg and leads to inhibition of gastric acid secretion.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="Section_12.2"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First"> <span class="Italics">Antisecretory Activity</span> <br />The effect of intravenous esomeprazole on intragastric pH was determined in two separate studies. In the first study, 20 mg of esomeprazole sodium for injection was administered intravenously once daily at constant rate over 30 minutes for 5 days. Twenty-two healthy subjects were included in the study. In the second study, 40 mg of esomeprazole sodium for injection was administered intravenously once daily at constant rate over 30 minutes for 5 days. Thirty-eight healthy subjects were included in the study.</p>    <br />    <div class="scrollingtable">    <table border="0" cellpadding="0" cellspacing="0" width="476">      <caption>       <span>Table 3: Effect of Esomeprazole Sodium for Injection on Intragastric pH on Day 5 </span>      </caption>      <tbody class="Headless">       <tr class="Botrule First">        <td class="Lrule Rrule" valign="top">&nbsp;<br /> </td>       <td class="Rrule" align="center" valign="top">Esomeprazole 20 mg (n=22)<br /> </td>       <td class="Rrule" align="center" valign="top">Esomeprazole 40 mg (n=38)<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">% Time Gastric pH&gt;4 <br /> </td>       <td class="Rrule" align="center" valign="top">49.5<br /> </td>       <td class="Rrule" align="center" valign="top">66.2<br /> </td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" valign="top">(95% CI) <br /> </td>       <td class="Rrule" align="center" valign="top">41.9 to 57.2<br /> </td>       <td class="Rrule" align="center" valign="top">62.4 to 70<br /> </td>       </tr>      </tbody>     </table>   </div>    <br />    <p>Gastric pH was measured over a 24-hour period<br /> <br /> <span class="Italics">Serum Gastrin Effects</span> <br />In oral studies, the effect of esomeprazole magnesium on serum gastrin concentrations was evaluated in approximately 2,700 patients in clinical trials up to 8 weeks and in over 1,300 patients for up to 6 to 12 months. The mean fasting gastrin level increased in a dose-related manner. This increase reached a plateau within two to three months of therapy and returned to baseline levels within four weeks after discontinuation of therapy.<br /> <br />Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors.<br /> <br /> <span class="Italics">Enterochromaffin-like (ECL) Cell Effects</span> <br />There are no data available on the effects of intravenous esomeprazole on ECL cells.<br /> <br />In 24-month carcinogenicity studies of oral omeprazole in rats, a dose-related significant occurrence of gastric ECL cell carcinoid tumors and ECL cell hyperplasia was observed in both male and female animals [<span class="Italics">see Nonclinical Toxicology, (13.1)</span>]. Carcinoid tumors have also been observed in rats subjected to fundectomy or long-term treatment with other proton pump inhibitors or high doses of H<span class="Sub">2</span>-receptor antagonists.<br /> <br />Human gastric biopsy specimens have been obtained from more than 3,000 patients treated orally with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients.<br /> <br />In over 1,000 patients treated with esomeprazole magnesium (10, 20 or 40 mg/day) up to 6 to 12 months, the prevalence of ECL cell hyperplasia increased with time and dose. No patient developed ECL cell carcinoids, dysplasia, or neoplasia in the gastric mucosa.<br /> <br /> <span class="Italics">Endocrine Effects</span> <br />Esomeprazole magnesium had no effect on thyroid function when given in oral doses of 20 mg or 40 mg for 4 weeks. Other effects of esomeprazole magnesium on the endocrine system were assessed using omeprazole studies. Omeprazole given in oral doses of 30 mg or 40 mg for 2 to 4 weeks had no effect on carbohydrate metabolism, circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.</p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="Section_12.3"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First"> <span class="Italics">Absorption</span> <br />The pharmacokinetic profile of esomeprazole sodium for injection 20 mg and 40 mg was determined in 24 healthy volunteers for the 20 mg dose and 38 healthy volunteers for the 40 mg dose following once daily administration of 20 mg and 40 mg of esomeprazole sodium for injection by constant rate over 30 minutes for five days. The results are shown in the following table:</p>    <br />    <div class="scrollingtable">    <table border="0" cellpadding="0" cellspacing="0" width="485">      <caption>       <span>Table 4: Pharmacokinetic Parameters of Esomeprazole Sodium Following I.V. Dosing for 5 days </span>      </caption>      <tbody class="Headless">       <tr class="Botrule First">        <td class="Lrule Rrule" valign="top">Parameter<br /> </td>       <td class="Rrule" align="center" valign="top">Esomeprazole Sodium for Injection 20 mg<br /> </td>       <td class="Rrule" align="center" valign="top">Esomeprazole Sodium for Injection 40 mg<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">AUC (μmol*h/L)<br /> </td>       <td class="Rrule" align="center" valign="top">5.11 (3.96:6.61)<br /> </td>       <td class="Rrule" align="center" valign="top">16.21 (14.46:18.16)<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" valign="top">C<span class="Sub">max</span> (μmol/L) <br /> </td>       <td class="Rrule" align="center" valign="top">3.86 (3.16:4.72)<br /> </td>       <td class="Rrule" align="center" valign="top">7.51 (6.93:8.13)<br /> </td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" valign="top">t<span class="Sub">1/2 </span>(h) <br /> </td>       <td class="Rrule" align="center" valign="top">1.05 (0.9:1.22)<br /> </td>       <td class="Rrule" align="center" valign="top">1.41 (1.3:1.52)<br /> </td>       </tr>      </tbody>     </table>   </div>    <br />    <p>Values represent the geometric mean (95% CI)<br /> <br /> <span class="Italics">Distribution</span> <br />Esomeprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 2&shy; to 20 μmol/L. The apparent volume of distribution at steady state in healthy volunteers is approximately 16 L.<br /> <br /> <span class="Italics">Metabolism</span> <br />Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The metabolites of esomeprazole lack antisecretory activity. The major part of esomeprazole’s metabolism is dependent upon the CYP2C19 isoenzyme, which forms the hydroxy and desmethyl metabolites. The remaining amount is dependent on CYP3A4 which forms the sulphone metabolite. CYP2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15 to 20% of Asians lack CYP2C19 and are termed Poor Metabolizers. At steady state, the ratio of AUC in Poor Metabolizers to AUC in the rest of the population (Extensive metabolizers) is approximately 2.<br /> <br />Following administration of equimolar doses, the S- and R-isomers are metabolized differently by the liver, resulting in higher plasma levels of the S- than of the R-isomer.<br /> <br /> <span class="Italics">Excretion</span> <br />Esomeprazole is excreted as metabolites primarily in urine but also in feces. Less than 1% of parent drug is excreted in the urine. Esomeprazole is completely eliminated from plasma, and there is no accumulation during once daily administration. The plasma elimination half-life of intravenous esomeprazole is approximately 1.1 to 1.4 hours and is prolonged with increasing dose of intravenous esomeprazole.<br /> <br /> <span class="Bold">Concomitant Use with Clopidogrel</span> <br />Results from a crossover study in healthy subjects have shown a pharmacokinetic interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole&nbsp;(40 mg p.o. once daily) when co-administered for 30 days. Exposure to the active metabolite of clopidogrel was reduced by 35% to 40% over this time period. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation was related to the change in the exposure to clopidogrel active metabolite.<br /> <br /> <span class="Italics">Special Populations</span> <br />Investigation of age, gender, race, renal, and hepatic impairment and metabolizer status has been made previously with oral esomeprazole. The pharmacokinetics of esomeprazole is not expected to be affected differently by intrinsic or extrinsic factors after intravenous administration compared to oral administration. The same recommendations for dose adjustment in special populations are suggested for intravenous esomeprazole as for oral esomeprazole.<br /> <br /> <span class="Italics">Geriatric</span> <br />In oral studies, the AUC and C<span class="Sub">max</span> values were slightly higher (25% and 18%, respectively) in the elderly as compared to younger subjects at steady state. Dosage adjustment based on age is not necessary.<br /> <br /> <span class="Italics">Pediatric</span> <br />In a randomized, open-label, multi-national, repeated dose study, esomeprazole PK was evaluated following a once-daily 3-minute injection in a total of 50 pediatric patients 0 to 17 years old, inclusive. Esomeprazole plasma AUC values for 20 mg esomeprazole sodium for injection were 183% and 60% higher in pediatric patients aged 6 to 11 years and 12 to 17 years respectively compared to adults given 20 mg. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 0.5 mg/kg once-daily for pediatric patients 1 to 11 months of age, 10 mg for pediatric patients 1 to 17 years with body weight ≤55 kg, and 20 mg for pediatric patients 1 to 17 years with body ≥55 kg would achieve comparable steady-state plasma exposures (AUC<span class="Sub">0-24</span>) to those observed in adult patients administered 20 mg of esomeprazole sodium for injection once every 24 hours. Further, increasing the infusion duration from 3 minutes to 10 minutes or 30 minutes was predicted to produce steady-state C<span class="Sub">max</span> values that were comparable to those observed in adult patients at the 40 mg and 20 mg esomeprazole sodium for injection doses.<br /> <br /> <span class="Italics">Gender</span> <br />In oral studies, the AUC and C<span class="Sub">max</span> values were slightly higher (13%) in females than in males at steady state. Similar differences have been seen for intravenous administration of esomeprazole. Dosage adjustment based on gender is not necessary.<br /> <br /> <span class="Italics">Hepatic Insufficiency</span> <br />In oral studies, the steady state pharmacokinetics of esomeprazole obtained after administration of 40 mg once daily to 4 patients each with mild (Child Pugh Class A), moderate (Child Pugh Class B), and severe (Child Pugh Class C) liver insufficiency were compared to those obtained in 36 male and female GERD patients with normal liver function. In patients with mild and moderate hepatic insufficiency, the AUCs were within the range that could be expected in patients with normal liver function. In patients with severe hepatic insufficiency the AUCs were 2 to 3 times higher than in the patients with normal liver function. No dosage adjustment is recommended for patients with mild to moderate hepatic insufficiency (Child Pugh Classes A and B). However, in patients with severe hepatic insufficiency (Child Pugh Class C) a dose of 20 mg once daily should not be exceeded [<span class="Italics">see <a href="#Section_2">Dosage and Administration (2)</a> and <a href="#Section_8.6">Use in Specific Populations (8.6)</a></span>].<br /> <br /> <span class="Italics">Renal Insufficiency</span> <br />The pharmacokinetics of esomeprazole in patients with renal impairment are not expected to be altered relative to healthy volunteers as less than 1% of esomeprazole is excreted unchanged in urine.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="Section_12.4"></a>   <a name="section-11.4"></a>    <p></p>    <h2>12.4 Microbiology </h2>    <p class="First"> <span class="Italics">Effects on Gastrointestinal Microbial Ecology</span> <br />Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <span class="Italics">Salmonella </span>and <span class="Italics">Campylobacter </span>and, in hospitalized patients, possibly also <span class="Italics">Clostridium difficile</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="Section_13"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="Section_13.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First">The carcinogenic potential of esomeprazole was assessed using omeprazole studies. In two 24-month oral carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44, and 140.8 mg/kg/day (about 0.7 to 57 times the human dose of 20 mg/day expressed on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (about 5.6 times the human dose on a body surface area basis) for 1 year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell hyperplasia was observed at the end of 1 year (94% treated vs 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs 26%) but still showed more hyperplasia in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for 2 years. For this strain of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. A 78-week oral mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive.<br /> <br />Esomeprazole was negative in the Ames mutation test, in the <span class="Italics">in vivo</span> rat bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo</span> mouse micronucleus test. Esomeprazole, however, was positive in the <span class="Italics">in vitro</span> human lymphocyte chromosome aberration test. Omeprazole was positive in the <span class="Italics">in vitro </span>human lymphocyte chromosome aberration test, the <span class="Italics">in vivo</span> mouse bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo </span>mouse micronucleus test.<br /> <br />The potential effects of esomeprazole on fertility and reproductive performance were assessed using omeprazole studies. Omeprazole at oral doses up to 138 mg/kg/day in rats (about 56 times the human dose on a body surface area basis) was found to have no effect on reproductive performance of parental animals.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="Section_14"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="Section_14.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Acid Suppression in Gastroesophageal Reflux Disease (GERD) </h2>    <p class="First">Four multicenter, open-label, two-period crossover studies were conducted to compare the pharmacodynamic efficacy of the intravenous formulation of esomeprazole (20 mg and 40 mg) to that of esomeprazole magnesium delayed-release capsules at corresponding doses in patients with symptoms of GERD, with or without erosive esophagitis. The patients (n=206, 18 to 72 years old; 112 female; 110 Caucasian, 50 Black, 10 Asian, and 36 Other Race) were randomized to receive either 20 mg or 40 mg of intravenous or oral esomeprazole once daily for 10 days (Period 1), and then were switched in Period 2 to the other formulation for 10 days, matching their respective dose level from Period 1. The intravenous formulation was administered as a 3-minute injection in two of the studies, and as a 15-minute infusion in the other two studies. Basal acid output (BAO) and maximal acid output (MAO) were determined 22 to 24 hours post-dose on Period 1, Day 11; on Period 2, Day 3; and on Period 2, Day 11. BAO and MAO were estimated from 1-hour continuous collections of gastric contents prior to and following (respectively) subcutaneous injection of 6 mcg/kg of pentagastrin.<br /> <br />In these studies, after 10 days of once daily administration, the intravenous dosage forms of esomeprazole sodium 20 mg and 40 mg were similar to the corresponding oral dosage forms in their ability to suppress BAO and MAO in these GERD patients (see table below).<br /> <br />There were no major changes in acid suppression when switching between intravenous and oral dosage forms.</p>    <br />    <br />    <div class="scrollingtable">    <table border="0" cellpadding="0" cellspacing="0" width="100%">      <caption>       <span>Table 5: Mean (SD) BAO and MAO measured 22 to 24 hours post-dose following once daily oral and intravenous administration of esomeprazole for 10 days in GERD patients with or without a history of erosive esophagitis </span>      </caption>      <tbody class="Headless">       <tr class="Botrule First">        <td class="Lrule Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Study</span> <br /> </td>       <td class="Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Dose in mg</span> <br /> </td>       <td class="Rrule" align="center" rowspan="2" valign="top"><span class="Bold">Intravenous Administration Method</span> <br /> </td>       <td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">BAO in mmol H+/h</span> <br /> </td>       <td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">MAO in mmol H+/h</span> <br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Intravenous</span> <br /> </td>       <td class="Rrule" align="center" valign="top"><span class="Bold">Oral</span> <br /> </td>       <td class="Rrule" align="center" valign="top"><span class="Bold">Intravenous</span> <br /> </td>       <td class="Rrule" align="center" valign="top"><span class="Bold">Oral</span> <br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="center" valign="top">1 (N=42)<br /> </td>       <td class="Rrule" align="center" valign="top">20<br /> </td>       <td class="Rrule" align="center" valign="top">3-minute injection<br /> </td>       <td class="Rrule" align="center" valign="top">0.71 (1.24)<br /> </td>       <td class="Rrule" align="center" valign="top">0.69 (1.24)<br /> </td>       <td class="Rrule" align="center" valign="top">5.96 (5.41)<br /> </td>       <td class="Rrule" align="center" valign="top">5.27 (5.39)<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="center" valign="top">2 (N=44)<br /> </td>       <td class="Rrule" align="center" valign="top">20<br /> </td>       <td class="Rrule" align="center" valign="top">15-minute infusion<br /> </td>       <td class="Rrule" align="center" valign="top">0.78 (1.38)<br /> </td>       <td class="Rrule" align="center" valign="top">0.82 (1.34)<br /> </td>       <td class="Rrule" align="center" valign="top">5.95 (4)<br /> </td>       <td class="Rrule" align="center" valign="top">5.26 (4.12)<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="center" valign="top">3 (N=50)<br /> </td>       <td class="Rrule" align="center" valign="top">40<br /> </td>       <td class="Rrule" align="center" valign="top">3-minute injection<br /> </td>       <td class="Rrule" align="center" valign="top">0.36 (0.61)<br /> </td>       <td class="Rrule" align="center" valign="top">0.31 (0.55)<br /> </td>       <td class="Rrule" align="center" valign="top">5.06 (3.9)<br /> </td>       <td class="Rrule" align="center" valign="top">4.41 (3.11)<br /> </td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="center" valign="top">4 (N=47)<br /> </td>       <td class="Rrule" align="center" valign="top">40<br /> </td>       <td class="Rrule" align="center" valign="top">15-minute infusion<br /> </td>       <td class="Rrule" align="center" valign="top">0.36 (0.79)<br /> </td>       <td class="Rrule" align="center" valign="top">0.22 (0.39)<br /> </td>       <td class="Rrule" align="center" valign="top">4.74 (3.65)<br /> </td>       <td class="Rrule" align="center" valign="top">3.52 (2.86)<br /> </td>       </tr>      </tbody>     </table>   </div>    <br />   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="Section_16"></a>  <a name="section-14"></a>   <p></p>    <br />   <p class="First">Esomeprazole sodium for injection is supplied as a white to off-white, freeze-dried cake containing 20 mg or 40&nbsp;mg of esomeprazole per single-use vial.<br /> <br /> <span class="Bold">NDC 47335-508-44</span> one carton containing 10 vials of esomeprazole sodium for injection (each vial contains 20 mg of esomeprazole).<br /> <br /> <span class="Bold">NDC 47335-509-44</span> one carton containing 10 vials of esomeprazole sodium for injection (each vial contains 40 mg of esomeprazole).<br /> <br /> <span class="Bold">Storage</span> <br />Store at 20&deg; to 25&deg;C (68&deg; to 77&deg;F); excursions permitted between 15&deg; and 30&deg;C (59&deg; and 86&deg;F) [See USP Controlled Room Temperature]. Protect from light. Store in carton until time of use.<br /> <br />Following reconstitution and administration, discard any unused portion of esomeprazole solution.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="Section_17"></a>  <a name="section-15"></a>   <p></p>    <ul class="Disc">    <li>Advise patients to let their healthcare provider know if they are taking, or begin taking other medications, because esomeprazole can interfere with antiretroviral drugs and drugs that are affected by gastric pH changes [<span class="Italics">see <a href="#Section_7">Drug Interactions (7)</a></span>].</li>    <li>Let patients know that antacids may be used while taking esomeprazole sodium for injection. </li>   </ul>   <p class="First">Advise patients to immediately report and seek care for diarrhea that does not improve. This may be a sign of <span class="Italics">Clostridium difficile </span>associated diarrhea [<span class="Italics">see <a href="#Section_5.8">Warnings and Precautions (5.3)</a></span>].<br /> <br />Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including palpitations, dizziness, seizures, and tetany as these may be signs of hypomagnesemia [<span class="Italics">see <a href="#Section_5.4">Warnings and Precautions (5.6)</a></span>]. <br /> <br />Distributed by: <br /> <span class="Bold">Caraco Pharmaceutical Laboratories, Ltd.</span> <br />1150 Elijah McCoy Drive, Detroit, MI 48202<br /> <br />Manufactured by:<br /> <span class="Bold">Sun Pharmaceutical Ind. Ltd.<br /> </span>Halol-Baroda Highway,<br />Halol-389 350, Gujarat, India.<br /> <br />ISS. 10/2013<br />PJPI0275</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-20 mg Carton</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="Section_19"></a>  <a name="section-16"></a>   <p></p>    <br />   <p class="First">NDC 47335-508-44<br />Esomeprazole Sodium for Injection<br />20 mg/vial<br />For Intravenous Use Only.<br />STERILE<br />LYOPHILIZED<br />Rx only<br />10 x 20 mg Single-Use Vials<br />SUN PHARMA</p>   <br />   <div class="Figure">    <img src="image.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&name=20mgcarton%2Ejpg" alt="20mgcarton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-40 mg Carton</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="Section_20"></a>  <a name="section-17"></a>   <p></p>    <br />   <br />   <p class="First">NDC 47335-509-44<br />Esomeprazole Sodium for Injection<br />40 mg/vial<br />For Intravenous Use Only.<br />STERILE<br />LYOPHILIZED<br />Rx only<br />10 x 40 mg Single-Use Vials<br />SUN PHARMA</p>   <br />   <div class="Figure">    <img src="image.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300&name=40mgcarton%2Ejpg" alt="40mgcarton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ESOMEPRAZOLE SODIUM&nbsp; </strong> <br /> <span class="contentTableReg">esomeprazole sodium injection, powder, lyophilized, for solution</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:47335-508</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAVENOUS</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ESOMEPRAZOLE SODIUM</strong> (UNII: L2C9GWQ43H) (ESOMEPRAZOLE - UNII:N3PA6559FT)</td>          <td class="formItem">ESOMEPRAZOLE</td>          <td class="formItem">20&nbsp;mg &nbsp;in&nbsp;5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>EDETATE DISODIUM</strong> (UNII: 7FLD91C86K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SODIUM HYDROXIDE</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:47335-508-44</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:47335-508-40</td>          <td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA200882</td>          <td class="formItem">01/03/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ESOMEPRAZOLE SODIUM&nbsp; </strong> <br /> <span class="contentTableReg">esomeprazole sodium injection, powder, lyophilized, for solution</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:47335-509</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAVENOUS</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ESOMEPRAZOLE SODIUM</strong> (UNII: L2C9GWQ43H) (ESOMEPRAZOLE - UNII:N3PA6559FT)</td>          <td class="formItem">ESOMEPRAZOLE</td>          <td class="formItem">40&nbsp;mg &nbsp;in&nbsp;5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>EDETATE DISODIUM</strong> (UNII: 7FLD91C86K)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SODIUM HYDROXIDE</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:47335-509-44</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:47335-509-40</td>          <td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA200882</td>          <td class="formItem">01/03/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Sun Pharma Global FZE (864347344) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Sun Pharmaceutical Industries Limited</td>      <td class="formItem"></td>      <td class="formItem">725959238</td>      <td class="formItem">ANALYSIS(47335-508) , MANUFACTURE(47335-508)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ESOMEPRAZOLE%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=ESOMEPRAZOLE" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=ESOMEPRAZOLE" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00363&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution <br></h3>            <h4>Number of versions: 1</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jan 22, 2014</td>                        <td>							                                6                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=129510">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                        <tr>                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=486499">486499</a></td>                              <td>Esomeprazole 4 MG/ML Injectable Solution</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=486499">486499</a></td>                              <td>esomeprazole 20 MG (as esomeprazole sodium 21.3 MG) per 5 ML Injectable Solution</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=486501">486501</a></td>                              <td>Esomeprazole 8 MG/ML Injectable Solution</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=486501">486501</a></td>                              <td>esomeprazole 40 MG (as esomeprazole sodium 42.5 MG) per 5 ML Injectable Solution</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">ESOMEPRAZOLE SODIUM - esomeprazole sodium injection, powder, lyophilized, for solution <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=069d7015-a2e4-4dbb-8255-2172e22a6300</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AESOMEPRAZOLE%20SODIUM%20%2D%20Esomeprazole%20Sodium%20Injection%2C%20Powder%2C%20Lyophilized%2C%20For%20So%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D069d7015%2Da2e4%2D4dbb%2D8255%2D2172e22a6300%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    